“I Thought It Was Only Good at Making Medicine”... A Pharmaceutical Company Finds Success With Cosmetics
- Input
- 2026-11-17 09:00:16
- Updated
- 2026-11-17 09:00:16

[Financial News] On the 17th, IBK Investment & Securities maintained its Buy rating and target price of 30,000 won for Dongkook Pharmaceutical, expecting growth in its cosmetics business despite weak performance at its subsidiaries.
Dongkook Pharmaceutical’s consolidated revenue for the third quarter was 258.7 billion won, up approximately 14.0% from the same period a year earlier. Operating profit, however, fell 4.1% to 23.8 billion won, below consensus.
Jeong I-su, an analyst at IBK Investment & Securities, said, “Its subsidiary Dongkook Life Science posted an operating loss of 1.6 billion won as the diagnostic equipment market deteriorated, weighing on profitability,” adding, “The consolidated operating margin was 9.2%, below the 10.4% margin on a standalone basis.”
Jeong noted, “Top-line growth was driven by the healthcare division, which rose 37% from the same period a year earlier,” and added, “Cosmetics sales in particular reached 79.5 billion won, up 66% from a year earlier, as the effects of overseas market expansion began to materialize. Healthcare’s share of total revenue rose to 39.3% from 32.7% a year earlier.”
Healthcare is expected to continue growing in the fourth quarter. Consolidated revenue is forecast to reach 275 billion won and operating profit 27.5 billion won, each up 13.2% from a year earlier.
Analyst Jeong said, “Sales of over-the-counter (OTC) and prescription (ETC) drugs are expected to remain steady at 46.5 billion won and 64.5 billion won, respectively,” and forecast, “Healthcare revenue will reach 112.5 billion won, supported by an expanded overseas distribution network and year-end peak-season demand, driving growth across the company.”
Jeong added, “Given this trend, annual healthcare exports are expected to exceed 120 billion won,” and continued, “Profitability is expected to improve through operating leverage as healthcare sales increase, but the extent of improvement in consolidated earnings may depend on whether Dongkook Life Science’s performance recovers.”
[email protected] Seo Min-ji Reporter